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Abstract Migraine is a painful and debilitating, neuro-
vascular disease. Current migraine head pain treatments
work with differing efficacies in migraineurs. The opioid
system plays an important role in diverse biological func-
tions including analgesia, drug response and pain reduction.
The A118G single nucleotide polymorphism (SNP) in exon 1
of the l-opioid receptor gene (OPRM1) has been associated
with elevated pain responses and decreased pain threshold in
a variety of populations. The aim of the current preliminary
study was to test whether genotypes of the OPRM1 A118G
SNP are associated with head pain severity in a clinical
cohort of female migraineurs. This was a preliminary study
to determine whether genotypes of the OPRM1 A118G SNP
are associated with head pain severity in a clinical cohort of
female migraineurs. A total of 153 chronic migraine with
aura sufferers were assessed for migraine head pain using the
Migraine Disability Assessment Score instrument and clas-
sified into high and low pain severity groups. DNA was
extracted and genotypes obtained for the A118G SNP.
Logistic regression analysis adjusting for age effects showed
the A118G SNP of the OPRM1 gene to be significantly
associated with migraine pain severity in the test population
(P = 0.0037). In particular, G118 allele carriers were more
likely to be high pain sufferers compared to homozygous
carriers of the A118 allele (OR = 3.125, 95 % CI = 1.41,
6.93, P = 0.0037). These findings suggest that A118G
genotypes of the OPRM1 gene may influence migraine-
associated head pain in females. Further investigations are
required to fully understand the effect of this gene variant on
migraine head pain including studies in males and in dif-
ferent migraine subtypes, as well as in response to head pain
medication.
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Introduction
Migraine is a chronic neurovascular disorder that is char-
acterised by unilateral throbbing headache associated with
features such as sensitivity to light and sound, nausea,
vomiting and neurological disturbances [1, 2]. The condi-
tion, which is classified into 2 main subtypes, migraine
with aura (MA) or without aura (MO), has a major impact
on the quality of life of patients and their families [3–5].
The pathogenesis of pain in migraine is still not fully
understood, but three key factors considered to play a part
include disruption of: the cranial blood vessels, the tri-
geminal innervation of the vessels, and the reflex connec-
tion of the trigeminal system in the cranial parasympathetic
outflow [1]. The main aim of acute migraine treatment,
such as non-steroidal anti-inflammatory drugs (NSAIDs),
aspirin and triptans, are rapid pain relief, improvement of
associated symptoms and prevention of migraine recur-
rence within 24 h [6]. Not all migraineurs find the current
medication options effective, which perhaps highlight the
multifactorial pathophysiology of migraine and suggest
that individual environmental and/or genetic factors may
influence treatment response [4].
An individual’s pain experience is shaped by psycho-
logical, behavioural and genetic factors [7]. Although there
is no conclusive evidence for the heritability of pain
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sensitivity in humans, studies have shown evidence that a
variety of thermal, mechanical and chemical pain-produc-
ing stimuli are genetically influenced in humans [8, 9].
Twin studies comparing the concordance rates of pain-
related traits in monozygotic versus dizygotic twins, in
order to separate the genetic and environmental factors,
have estimated heritability as 39–58 % for migraine
[10–12], 55 % for menstrual pain [13], 50 % for back pain
[14] and 21 % for sciatica [15]. In addition to twin studies,
recent research has examined the association between
single nucleotide polymorphisms (SNPs) of specific genes
and experimental pain responses. Kim et al. [16] in their
research reported heritability estimates of 22–46 % across
three pain modalities and found an association of a
d-opioid receptor gene (OPRD1) SNP with thermal pain
response among men, but not women. Zubieta et al. [17]
reported a SNP in the catechol-O-methyltransferase gene
(COMT) to be associated with pain self-report and pain-
induced brain l-opioid receptor binding during experi-
mental muscle pain induction. Thus, though limited, there
is some evidence for a genetic contribution to human pain
response.
The l-opioid receptor gene (OPRM1) is located on the
human chromosome 6q24-25. The OPRM1 receptor is the
site of action for many endogenous opioid peptides and a
significant target for opioid analgesics [18, 19]. Opioid
analgesics, such as morphine and codeine have been used
by clinicians to treat severe cases of migraine headache
[20]. The OPRM1 gene has been widely studied and
reported to be associated with pain sensitivity in humans
[21–23]. A commonly studied OPRM1 gene SNP is the
A118G in exon 1 that causes an Asn40Asp substitution at a
putative glycosylation site in the extracellular domain [24].
The A118G SNP in the OPRM1 gene has been widely
investigated and associated with elevated pain responses
and decreased pain thresholds [21, 22]. Some functional
consequences of this SNP include lower mRNA and protein
expression levels with the G118 variant [25]. The G118
variant also increases receptor affinity of b-endorphin by
threefold [24], which could potentially be the mechanism
by which this SNP may affect pain sensitivity [26].
Studies that investigated the relationship between pain
thresholds and analgesic responses to opioid administration
for the A118G SNP have in most instances associated the G
allele with decreased pain threshold and reduced response
to opioids for patients receiving post-operative care or
chronic pain [22, 27–29]. The OPRM1 gene ranks highly on
all three criteria introduced for prioritizing candidate genes
in association studies investigating pain, namely: strength
of evidence supporting involvement in pain sensitivity,
frequency of the specific variant, and evidence for func-
tional consequence of the SNP [26, 30]. However to date, no
studies have reported an association between the A118G
SNP and head pain associated with migraine, ranked 19th in
the world’s most disabling illness by the World Health
Organisation [4].
Studies have shown that certain gene mutations influ-
ence treatment suitability and options for some migraine
subtypes [31–33]. Understanding the effect of the A118G
SNP on pain sensitivity could aid in optimising pain
treatment for migraineurs. This study focussed on the
A118G SNP and migraine-associated head pain severity. A
total of 153 females with MA were studied to investigate
the association between A118G genotypes and head pain
severity. We selected only females because the disease is
far more prevalent in females and a far greater number of
female patients present at clinics with chronic head pain
associated with migraine [34]. Fillingm et al. (2000)
reviewed literature in sex, gender and pain and found
substantial sex differences in clinical and experimental
procedure [34]. A recent review also highlighted the con-
sistent literature showing higher prevalence of headaches
and migraine among women, who also reported higher
clinical pain intensities than men for a number of disease
entities [35]. There was a focus on MA so as not to
introduce confounding due to genetic and phenotypic dif-
ferences between the migraine subtypes.
Methods
Participants
This was a retrospective clinical epidemiologic study
focussing on a sample of 153 adult females diagnosed with
MA. All participants were Caucasian residents of Australia
(East Coast) with European ancestors from various loca-
tions within the British Isles and other parts of Europe.
Participants completed a detailed questionnaire that was
administered by a qualified diagnostician through Griffith
University’s Genomics Research Centre (GRC) clinical
trials unit. Participants were included if they had suffered
migraine for over 20 years and had a current diagnosis of
MA ([90 % of their migraine attacks were associated with
aura), and a 1-year history of severe, long lasting attacks (at
least 4 attacks lasting more than 48 h) and had a family
history of migraine.
A whole blood sample was collected from each partic-
ipant, for genomic DNA extraction from white blood cells,
according to an approved protocol for experimentation on
human participants. All participants gave their informed
and written consent for genetic analysis of their blood
samples. Participant’s medication use; frequency, quantity
and treatment compliance were also recorded. Participants
were excluded if they had been diagnosed with a clinically
recognized cardiovascular or neuropsychiatric condition
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such as depression or schizophrenia. The study was
approved by the Griffith University Ethics Committee for
Experimentation on Human Participants.
Assessment of head pain associated with migraine
All participants were assessed for migraine-related head
pain using the Migraine Disability Assessment Score
(MIDAS) instrument, which provides a measure of pain
severity, headache frequency and disability [31, 36, 37].
Studies have shown that this is a valid and clinically useful
instrument for assessing health-related quality of life in
migraineurs [36, 37].
Based on the 5-question MIDAS rating, participants
were arbitrarily categorized into a ‘low’ disability group if
they had a MIDAS rating of 0–10 and into a ‘high’ dis-
ability group if they had a MIDAS rating greater than 11
[31, 36, 37]. Question 6 of the MIDAS instrument is on
migraine frequency. This is measured as number of days
with headache over a 3-month period [31, 36, 37]. The
outcome variable assessed in this study was migraine head
pain severity, question 7 on the MIDAS instrument, which
is measured as a self-reported pain score (based on a scale
of 0–10). The MIDAS migraine head pain severity question
is as stated ‘‘B. On a scale of 0–10, on average how painful
were these headaches? (Where 0 = no pain at all, and
10 = pain as bad as possible)’’ [31, 36, 37]. Patients were
asked to provide a head pain assessment prior to taking any
medication or treatment for their migraine attacks. Scoring
was retrospectively based on the patient’s untreated
migraine attacks in the 3-month period prior to recording.
OPRM1 A118G genotyping
Genomic DNA was obtained from leucocytes following a
salting out method as previously described by Miller et al.
[38]. Genotyping of the A118G SNP was conducted by
polymerase chain reaction (PCR). The A118G SNP was
amplified using the forward primer (50-GGTCAACTTGT
CCCACTTAGAT C GC- 30) which was designed to create
a restriction site for the enzyme Bst UI when the G118
allele is present and reverse primer (50-AATCACATA
CATGACCAGGAAGTTT-30) [39]. The PCR conditions
used were an initial denaturation at 94 C for 3 min, fol-
lowed by 38 cycles of 94 C for 30 s, 60 C for 1 min,
72 C for 1 min, with a final extension of 72 C for 10 min
[19]. Genotyping for the A118G polymorphism was per-
formed by digesting PCR products with the Bst UI
restriction enzyme (New England Biolabs, Beverly, MA,
USA). The enzyme recognises the CGCG sequence and
reacts at 60 C. The digested PCR products were resolved
using a 3 % agarose gel, stained with ethidium bromide
and visualised under ultra-violet light. The Bst UI digestion
of the A allele gave a band of 193 bp. The G allele gave
164 and 24 bp fragments. The results of each genotype
were confirmed in randomly selected subset of individuals
(10 %) via sequencing using an ABI-3130 Genetic Ana-
lyser. Sequence electrophoretograms were examined visu-
ally using the ABI Sequencing Analysis software 5.0 to
determine the alleles of the OPRM1 A118G SNP (Fig. 1).
Statistical analysis
Summary statistics was calculated for migraine head pain
severity in each of the three genotypic groups (A/A, A/G,
G/G). Hardy–Weinberg equilibrium (HWE) was verified
for observed genotype frequencies of the OPRM1 A118G
SNP to detect deviation from the expected genotype dis-
tribution and to detect genotyping error. Data for migraine
head pain severity in the AG and GG genotypes were
added together and presented as one category to test the
hypothesis that G allele carriers have a higher average
migraine head pain severity compared to non-carriers as
suggested by previous studies [21, 22]. Pain score data was
first evaluated for normality of the distribution and subse-
quently dichotomised into two categories based on the 50th
percentile of the distribution. All patients were assigned a
pain score code of 0 or 1, whereby 0 = low pain (a score
\7) and 1 = high pain (a score C7). To test the effects of
genotype on migraine pain severity, the v2 test was per-
formed using the pain score categories described above.
Odds ratios (OR) with their associated 95 % confidence
intervals (95 % CI) were calculated using logistic regres-
sion analysis with age included as a covariate. The
threshold of statistical significance was defined as 0.05, and
all analyses were performed using the Statistical Package
for Social Sciences (SPSS version 17.0).
Fig. 1 Agarose gel picture illustrating the different A118G genotypes
identified by RFLP using the Bst UI restriction enzyme. Column 1 is a
100 bp marker, column 2 shows a sample homozygote for the mutant
G118 allele, column 3 shows a sample heterozygote for the A118G
SNP and columns 4–8 are samples heterozygous for the wild-type
A118 allele
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Results
Among the 153 MA patients that were analysed in this study,
there were 119 (77.3 %) wild-type homozygotes (A/A), 32
(26.9 %) heterozygotes (A/G) and 2 (1.7 %) mutant homo-
zygotes (G/G). The genotype distribution for the group did
not deviate from HWE (P [ 0.9). Based on previous
research and the hypothesis that the G allele specifically is
associated with increased pain [21, 22], the A/G and the G/G
genotypes were grouped together and compared against the
A/A genotypes. This analysis showed that 64.7 % of the G
carriers had high head pain severity scores compared to 37 %
of the A/A carriers. Normality plots indicated that the pain
score data was not normally distributed (P \ 0.05) and
substantially asymmetrical (Fig. 2). For this reason the pain
scores were dichotomised as described in ‘‘Methods’’ before
further analysis. Logistic regression analysis showed that the
G allele (i.e. A/G and G/G) was significantly associated with
‘high’ migraine head pain severity (OR = 3.125, 95 %
CI = 1.41, 6.93, P = 0.0037) (Table 1). Age was included
as a covariate because of possible association of age on head
pain score (Table 2).
Discussion
This study investigated if the OPRM1 gene, A118G SNP
was associated with migraine head pain severity in females.
Specifically, the aim of this study was to elucidate the
propensity of the G allele in affecting head pain perception
in MA sufferers. A total of 153 female MA patients were
genotyped for the OPRM1 A118G SNP. The major finding
of this study was that genotypes of the A118G SNP were
associated with head pain severity in female MA sufferers,
whereby G118 allele carriers had demonstrably higher
likelihood of being high pain sufferers compared to the
homozygous A118 allele carriers.
The multi-factorial pathophysiology of migraine has
complicated diagnosis and treatment. A number of genes,
causative mutations and susceptibility variants have been
reported to work separately or in synergy to result in cer-
tain types of migraine [40]. Further studies on the genetic
contribution to migraine are necessary to understand the
complex pathophysiology of this disease. The human
OPRM1 gene is one of the primary candidates for phar-
macogenetic study and is the site of target for opioid
analgesics [20]. The relationships between altered pain
thresholds and responses to analgesic opioid administration
and the A118G SNP in the OPRM1 gene have been well
investigated and characterised [29]. The G118 allele has
been associated with increased pain responses and reduced
response to opioid analgesics in patients receiving treat-
ments for post-operative or chronic pain, in a variety of
populations over the last couple of years [26–28, 41–43].
Fig. 2 Normality plot of pain scores for the 153 female MA sufferers
in the study
Table 1 Clinical characteristics of patient group based on their
OPRM-1 A118G genotype
Variable A/A carriers A/G, G/G carriers
No. of patients 119 34
Age in years, mean (±SD) 43 (±14) 44 (±14)
Head pain score, median (range) 7 (1–10) 8 (3–10)
High head pain (%) 37 64.7
Table 2 Head pain scores for female MA patients by OPRM1 gene, A118G SNP genotype
Group Genotypes
Migraine pain severity score AA AG/GG Odds ratio* P value*
Low score (n %) 75 (63) 12 (35.2) 3.125 0.0037
High score (n %) 44 (37) 22 (64.7)
Total 119 34
Chi-squared (v2) analysis revealed significant association between genotypic frequencies for the A118G SNP in the OPRM1 gene and high scores
for head pain in MA females. Values are total number genotypes. Significance was taken at P B 0.05
* Odds ratio and P value adjusted for age
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A recent study that investigated the association of
A118G with self-rated postoperative pain and the amount
of self-administered morphine in females reported that the
A118G variant was associated with higher pain scores [22].
Contrastingly, Fillingim et al. [26] reported that healthy
volunteers with the G118 allele receiving different exper-
imental pain procedures had reduced pain responses to
pressure. Additionally the males in the experimental group
with the G allele rated thermal pain lower than those with
the A allele. However, the females carrying the G allele in
the experimental group reported elevated pain response
following thermal pain administration, consistent with
previous studies [26]. The change of quantity and binding
affinity of the l-opioid receptors brought about by the
A118G SNP has been implicated for the observed effects
of this SNP [19]. Further studies, however, are still war-
ranted to understand the exact molecular effect of the
A118G SNP on the OPRM1 gene function that may elu-
cidate the observed clinical effects of this SNP.
This is the first study to investigate the association
between the OPRM1 A118G SNP and migraine head pain
severity. The limitations of this study deserve mention. A
notable number of studies support the contention that the
human OPRM1 is a pain-relevant gene and that the A118G
SNP in the OPRM1 gene is potentially related to altered
opioid requirements for achieving analgesia and/or altered
pain perception mechanism. Hence the current study
focused only on the A118G SNP in the OPRM1 gene as a
prime candidate in investigating migraine pain. However,
the A118G SNP is only one of the more than 100 known
SNPs in the OPRM1 gene and therefore further studies are
required to investigate other candidate, albeit rare SNPs to
understand their influence on pain associated with
migraine. Secondly because, this is the first study associ-
ating the OPRM1 gene with migraine pain severity, repli-
cation in additional, larger populations is necessary to
enhance confidence in results. The fact that allele fre-
quency estimates of the A118G SNP in current study
population were similar to that of studies reported previ-
ously suggests that the population is homogeneous in
ancestry and the potential for confounding is minimal, it is
still not exempt from stratification completely.
Most of the participants in this study took some form of
pain relieving medication which are essentially taken
during a migraine attack and are designed to abort symp-
toms that have already begun. The common classes of
medicines taken by the participants of this study include
ergotamine, triptan and simple analgesics (non-steroidal
anti-inflammatory drugs, acetylsalicylic acid, paracetamol).
Pain scoring was retrospectively based on the patient’s
untreated migraine attacks in the 3-month period prior to
recording and therefore it was accepted that the pain score
recorded was not influenced by medication effects.
However, that is not to say that medication taken during a
migraine attack could not have lessened the associated
symptoms (i.e. head pain) before it reached a threshold that
required the participant to give a higher pain score.
Lastly, this study has been confined to only female MA
sufferers and as yet we do not know if this finding will be
replicated in female MO migraineurs and in male migrai-
neurs. Therefore, caution should be exercised when inter-
preting the results of this study. As such, this study has taken
the first step towards investigating the association between
the A118G SNP in the OPRM1 gene and migraine pain
severity and has provided initial evidence that the presence
of the G118 allele may increase the severity of migraine pain.
In conclusion the results from this study suggest that the
A118G genotypes of the OPRM1 gene may influence
migraine-associated head pain in females. Further investi-
gations are needed to fully understand the effect of this gene
variant on migraine head pain including studies in different
migraine subtypes and in males, as well as in response to head
pain medication to optimise treatment options.
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